Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio Medica LaboratoriesNSE:BMLL +1.21%18 Return-on-Tangible-Equity is 99.59% as of Mar. 2025, which is 47% above its 10-year median of 67.74. GuruFocus rates NSE:BMLL with a GF Score™ of 18/100. The stock has 7 warning signs investors should review. Among 757 Medical Devices & Instruments companies, Bio Medica Laboratories ranks better than 93.66% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Bio Medica Laboratories's annualized net income for the quarter that ended in Mar. 2025 was ₹97.9 Mil. Bio Medica Laboratories's average shareholder tangible equity for the quarter that ended in Mar. 2025 was ₹98.4 Mil. Therefore, Bio Medica Laboratories's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2025 was 99.59%.
The historical rank and industry rank for Bio Medica Laboratories's Return-on-Tangible-Equity or its related term are showing as below:
NSE:BMLL'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 13.67 Med: 67.74 Max: 99.59
Current: 99.59
During the past 3 years, Bio Medica Laboratories's highest Return-on-Tangible-Equity was 99.59%. The lowest was 13.67%. And the median was 67.74%.
NSE:BMLL's Return-on-Tangible-Equity is ranked better than 93.66% of 757
companies
in the Medical Devices & Instruments industry
Industry Median: 4.16
vs NSE:BMLL: 99.59
Bio Medica Laboratories (NSE:BMLL) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Bio Medica Laboratories Return-on-Tangible-Equity Related Terms
Bio Medica Laboratories Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Bio Medica Laboratories's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Medica Laboratories Return-on-Tangible-Equity Chart
Bio Medica Laboratories Annual Data
Trend
Mar23
Mar24
Mar25
Return-on-Tangible-Equity
13.67
67.74
99.59
Bio Medica Laboratories Semi-Annual Data
Mar23
Mar24
Mar25
Return-on-Tangible-Equity
13.67
67.74
99.59
NSE:BMLL vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Bio Medica Laboratories's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio Medica Laboratories Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio Medica Laboratories's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Bio Medica Laboratories's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is one times the annual (Mar. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 99.59% mean?
Bio Medica Laboratories (NSE:BMLL) has a Return-on-Tangible-Equity of 99.59% as of Mar. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bio Medica Laboratories and its competitors. This is 47% above median its historical median of 67.74. Over the past decade, Bio Medica Laboratories' Return-on-Tangible-Equity has ranged from 13.67 to 99.59. According to the industry distribution chart, Bio Medica Laboratories ranks #48 out of 757 companies in the Medical Devices & Instruments industry, placing it in the top 6.3%.
Is Bio Medica Laboratories' Return-on-Tangible-Equity too high?
Bio Medica Laboratories' current Return-on-Tangible-Equity of 99.59% is 47% above median its 10-year median of 67.74. Over the past 10 years, this metric has ranged from a low of 13.67 to a high of 99.59. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.16. Bio Medica Laboratories' value of 99.59% is 2294% above this industry median. Based on the distribution chart, Bio Medica Laboratories ranks #48 out of 757 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bio Medica Laboratories has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Bio Medica Laboratories' Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bio Medica Laboratories ranks #48 out of 757 companies for Return-on-Tangible-Equity. This places Bio Medica Laboratories in the top 6% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.16. Bio Medica Laboratories' value of 99.59% is 2294% above this benchmark. Historically, Bio Medica Laboratories' own Return-on-Tangible-Equity has ranged from 13.67 to 99.59 over the past decade. While the company's 10-year median is 67.74 vs. the industry median of 4.16, Bio Medica Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.16, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio Medica Laboratories's current Return-on-Tangible-Equity of 99.59% is 2294% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bio Medica Laboratories and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio Medica Laboratories's current Return-on-Tangible-Equity is 99.59%, which is 47% above median its own 10-year median of 67.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Medica Laboratories stock overvalued right now?
Bio Medica Laboratories (NSE:BMLL) has a current Return-on-Tangible-Equity of 99.59%. The current Return-on-Tangible-Equity is 99.59%, which is 47% above median its 10-year median of 67.74 and 2294% above the Medical Devices & Instruments industry median of 4.16. Bio Medica Laboratories' overall GF Score™ is 18/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Bio Medica Laboratories (NSE:BMLL), the current Return-on-Tangible-Equity is 99.59% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio Medica Laboratories Ltd is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. It manufactures generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a wide range of medical needs and preferences. The majority of revenue is derived from the sales of Liquid injections. Geographically, it operates predominantly in India, and internationally, it exports to Afghanistan.
18GF Score
Get the complete analysis for NSE:BMLL
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BMLL has been successfully added to your 
